证券代码：603102 证券简称：百合股份 公告编号：2025-043 威海百合生物技术股份有限公司 关于开展"提质增效重回报"专项行动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 威海百合生物技术股份有限公司（以下简称"公司"）为深入贯彻落实党中 央、国务院关于推动高质量发展、提升上市公司质量的决策部署，积极响应上海 证券交易所《关于开展沪市公司"提质增效重回报"专项行动倡议》，践行"以 投资者为本"的发展理念，进一步提升公司质量与投资价值，增强投资者获得感， 公司特制订"提质增效重回报"专项行动方案，并经公司董事会审议通过。具体 方案如下： 一、聚焦主业发展，提升经营质量 作为专注于营养保健食品研发、生产与销售的高新技术企业，公司产品剂型 丰富，全面覆盖软胶囊、硬胶囊、片剂、粉剂、口服液等主流剂型。公司始终坚 持以研发创新为驱动，紧密跟踪国内外健康消费趋势，持续进行新功能、新原料 产品的开发与技术储备，以满足全球消费者多元化、高品质的健康需求。公司于 2025 年 8 月 25 日完成对 Oranutrition ...

证券代码：603102 证券简称：百合股份 公告编号：2025-040 威海百合生物技术股份有限公司 第四届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 威海百合生物技术股份有限公司（以下简称"公司"）于 2025 年 11 月 21 日 向各位董事发出了召开第四届董事会第十五次会议的通知。2025 年 12 月 1 日， 第四届董事会第十五次会议以通讯及现场投票相结合的表决方式在公司会议室 召开，应出席本次会议的董事 9 人，实际出席本次会议的董事 9 人，公司相关高 级管理人员列席了本次会议。本次会议由董事长刘新力先生召集和主持，会议的 召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的有关规 定。 根据募集资金实际使用以及募投项目实施情况，为保证募投项目建设更符合 公司和股东利益，公司拟将首次公开发行股票募投项目中的"总部生产基地建设 项目"及"总部办公及运营配套建设项目"预计达到可使用状态时间调整为 2026 年 12 月。本次募投项目延期事项不改变募 ...

Group 1 - The core point of the article is that Baihe Co., Ltd. announced the postponement of some fundraising projects during its board meeting held on December 1, 2025 [1] - For the year 2024, Baihe Co., Ltd.'s revenue composition is primarily from nutritional health products, accounting for 99.27%, while other businesses contribute only 0.73% [1] - As of the report, Baihe Co., Ltd. has a market capitalization of 2.7 billion yuan [1]

Group 1 - The food processing sector increased by 0.31% on November 12, with Anjijia Food leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] - Anjijia Food's closing price was 81.22, reflecting a rise of 5.19% with a trading volume of 184,000 shares and a transaction value of 1.509 billion yuan [1] Group 2 - The food processing sector experienced a net outflow of 275 million yuan from institutional investors, while retail investors saw a net inflow of 239 million yuan [2] - The top gainers in the food processing sector included Qianwei Central Kitchen and Xianle Health, with closing prices of 41.48 and 25.23, respectively, reflecting increases of 2.75% and 1.77% [1] - The sector's main stocks showed varied performance, with some experiencing significant declines, such as Gaisijia Food, which fell by 7.31% [2]

Core Viewpoint - The food processing sector experienced a slight increase of 0.37% on November 11, with Gais Food leading the gains, while the overall market indices saw declines [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4002.76, down 0.39%, and the Shenzhen Component Index closed at 13289.0, down 1.03% [1]. - Gais Food's stock price rose by 4.89% to 15.86, with a trading volume of 270,200 shares and a transaction value of 419 million yuan [1]. Group 2: Individual Stock Performance - Other notable gainers included: - Kangbiter, up 4.65% to 18.92, with a trading volume of 53,400 shares and a transaction value of 99.55 million yuan [1]. - Babi Food, up 4.43% to 32.08, with a trading volume of 167,500 shares and a transaction value of 530 million yuan [1]. - Haixin Food, up 3.12% to 5.29, with a trading volume of 397,300 shares and a transaction value of 208 million yuan [1]. Group 3: Capital Flow - The food processing sector saw a net outflow of 159 million yuan from institutional investors, while retail investors contributed a net inflow of 100 million yuan [2]. - Gais Food had a net inflow of 25.86 million yuan from retail investors, indicating strong interest from individual investors [3].

Core Viewpoint - Baihe Co., Ltd. (603102.SH) reported a decline in institutional ownership in its Q3 2025 financial results, with a total of 695,200 shares held by two institutional investors, representing 1.09% of the total share capital, down 1.51 percentage points from the previous quarter [1] Institutional Ownership - As of October 29, 2025, two institutional investors disclosed their holdings in Baihe Co., Ltd., with a combined ownership of 695,200 shares [1] - The institutional investors include Rongcheng City Yongli Investment Management Co., Ltd. and Nuoan Active Allocation Mixed A [1] - The total institutional ownership percentage decreased by 1.51 percentage points compared to the previous quarter [1] Public Fund Holdings - One new public fund disclosed its holdings this quarter, namely Nuoan Active Allocation Mixed A [1] - A total of 71 public funds were not disclosed in this quarter compared to the previous quarter, including Hai Futong Growth Value Mixed A, Bank of China China Mixed (LOF) A, Xinhua Preferred Consumer Mixed, Nuoan Balanced Mixed A, and Hai Futong Consumer Preferred Mixed A [1]

Core Viewpoint - The announcement provides an overview of the financial performance and operational data of Weihai Bihua Biotechnology Co., Ltd. for the third quarter of 2025, emphasizing the accuracy and completeness of the reported information [1][2][8]. Financial Data Summary - The financial statements for the third quarter of 2025 are unaudited, covering the period from the beginning to the end of the quarter [3][7]. - The company confirms that there are no significant changes in the financial indicators compared to previous periods, and the financial information is guaranteed to be true and complete by the management [2][5]. Operational Performance - The announcement includes key operational data categorized by product type, sales model, and regional distribution, although specific figures are not provided in the text [8]. - The company has reported changes in the number of distributors during the third quarter, indicating adjustments in its distribution network [8]. Management Assurance - The board of directors and senior management affirm their responsibility for the accuracy and completeness of the quarterly report, ensuring that there are no misleading statements or omissions [1][2].

Core Viewpoint - Baihe Co., Ltd. is a significant player in the nutritional health food industry, with a strong focus on research and development, and a diverse product range that is exported to over 70 countries [1] Financial Performance - For Q3 2025, Baihe's revenue reached 645 million yuan, ranking 7th among 9 companies in the industry, while the net profit was 98.96 million yuan, placing it 5th [2] - The revenue breakdown includes soft capsules at 151 million yuan (35.97%), functional drinks at 120 million yuan (28.56%), and other products [2] Debt and Profitability - The company's debt-to-asset ratio stood at 13.80% in Q3 2025, lower than the industry average of 30.87%, indicating low debt pressure [3] - The gross profit margin was 35.12%, below the industry average of 38.90%, suggesting room for improvement in profitability [3] Leadership and Compensation - Chairman Liu Xinli's compensation for 2024 was 1.87 million yuan, a decrease from 1.90 million yuan in 2023 [4] Shareholder Dynamics - As of September 30, 2025, the number of A-share shareholders decreased by 20.71% to 6,798, while the average number of shares held per shareholder increased by 125.07% [5] Business Highlights - In H1 2025, Baihe achieved revenue of 420 million yuan, a year-on-year increase of 2.06%, but net profit decreased by 13.37% to 72 million yuan [6] - The company is undergoing a strategic transformation with the launch of a new brand and has made a significant acquisition of a New Zealand health product company, Ora, which is expected to enhance revenue growth [5][6] - Revenue projections for 2025-2027 are 970 million, 1.35 billion, and 1.55 billion yuan, with corresponding net profits of 150 million, 200 million, and 230 million yuan [5][6]

一、公司 2025 年第三季度主要经营情况 | | | | | 单位：元 | 币种：人民币 | | | --- | --- | --- | --- | --- | --- | --- | | 产品分类 | 年 2025 7-9 | 月销售收入 | 年 2024 7-9 | 月销售收入 | 增减变动幅度（%） | | | 软胶囊 | | 68,806,380.75 | | 74,682,166.55 | | -7.87 | | 功能饮品 | | 66,405,865.99 | | 54,244,040.51 | | 22.42 | | 片剂 | | 21,877,101.94 | | 25,886,049.87 | | -15.49 | | 粉剂 | | 35,337,894.42 | | 21,287,246.43 | | 66.01 | | 硬胶囊 | | 14,267,627.50 | | 13,400,005.17 | | 6.47 | | 软糖 | | 15,087,236.75 | | 3,063,275.43 | | 392.52 | | 组合及其他 | | 426,967.21 | | 763, ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥225,000,613.13, representing a year-on-year increase of 15.71%[4] - The total profit for the period was ¥31,039,319.15, showing a decrease of 19.01% compared to the same period last year[4] - The net profit attributable to shareholders was ¥27,111,412.59, down 19.54% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥22,618,013.83, a decline of 23.76% compared to the previous year[4] - The basic earnings per share for the period was ¥0.43, a decrease of 18.87% compared to the same period last year[4] - The weighted average return on equity was 1.62%, down 0.53 percentage points from the previous year[4] - The net profit for the first three quarters of 2025 is CNY 98,957,898.62, a decrease of 15.1% compared to CNY 116,665,969.26 in the same period of 2024[22] - The total comprehensive income for the first three quarters of 2025 is CNY 97,889,643.77, down from CNY 116,665,969.26 in the previous year[23] - Basic and diluted earnings per share for the first three quarters of 2025 are both CNY 1.58, compared to CNY 1.82 in the same period of 2024[23] - Operating profit for the first three quarters of 2025 was ¥112,777,486.36, a decrease of 15.1% from ¥132,941,899.75 in the previous year[31] - Net profit for the first three quarters of 2025 was ¥101,700,823.78, down 12.8% from ¥116,663,033.63 in 2024[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,917,679,939.73, an increase of 5.61% from the end of the previous year[5] - The equity attributable to shareholders was ¥1,627,593,234.51, reflecting a growth of 1.35% year-on-year[5] - The company's total assets as of September 30, 2025, amounted to RMB 1,917,679,939.73, compared to RMB 1,815,740,918.83 at the end of 2024[18] - Current assets totaled RMB 1,376,680,541.00, slightly up from RMB 1,353,749,169.17 at the end of 2024[15] - The company's total liabilities increased to RMB 264,667,968.60 from RMB 209,808,725.05 in the previous year[17] - The equity attributable to shareholders reached RMB 1,627,593,234.51, compared to RMB 1,605,932,193.78 at the end of 2024[18] - Total liabilities increased to ¥212,579,692.69 from ¥208,238,785.02, indicating a rise of 2.0%[29] - The company's total equity reached ¥1,642,211,997.82, an increase from ¥1,617,241,604.01, representing a growth of 1.5%[29] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥143,454,307.47, an increase of 46.23%[9] - Cash flow from operating activities for the first three quarters of 2025 is CNY 143,454,307.47, an increase of 46.2% from CNY 98,099,252.31 in 2024[25] - The cash inflow from operating activities was ¥680,156,753.46, compared to ¥609,048,066.15 in the previous year, showing an increase of 11.7%[34] - The net cash flow from operating activities increased to ¥135,073,773.17 in 2025, compared to ¥98,024,253.82 in 2024, marking a growth of 37.8%[34] Research and Development - Research and development expenses increased to RMB 27,511,855.71, representing a rise of 21.07% compared to RMB 22,656,587.50 in 2024[21] - Research and development expenses for the first three quarters of 2025 were ¥27,037,263.80, up 19.5% from ¥22,656,587.50 in 2024[30] Government Support and Future Outlook - The company received government subsidies amounting to ¥4,300,711.32 year-to-date, which positively impacted its financial performance[7] - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance growth[21] Inventory and Other Financial Metrics - Inventory as of September 30, 2025, was RMB 141,558,812.34, up from RMB 115,115,392.58 at the end of 2024[15] - The company reported a credit impairment loss of CNY -190,088.57 for the first three quarters of 2025, a significant improvement from CNY -1,028,421.19 in 2024[22] - The total operating revenue for the first three quarters of 2025 reached RMB 645,349,650.92, an increase of 6.43% compared to RMB 606,326,448.41 in the same period of 2024[21] - Total operating costs for the first three quarters of 2025 were RMB 534,627,006.09, up 11.43% from RMB 479,812,904.79 in the previous year[21] - The company has made investments totaling CNY 50,000,000.00 in the first three quarters of 2025, consistent with the previous year[25] Cash and Financing Activities - Cash and cash equivalents at the end of September 2025 amount to CNY 1,061,378,359.47, a decrease from CNY 1,079,643,744.48 at the end of 2024[26] - Net cash outflow from investing activities for the first three quarters of 2025 is CNY -142,250,390.25, compared to CNY -104,968,272.32 in 2024[25] - Net cash flow from financing activities was -$72.32 million, compared to -$48.13 million in the previous period, indicating a significant increase in cash outflows[35] - Total cash and cash equivalents at the end of the period decreased to $1.05 billion from $1.07 billion, reflecting a net decrease of $88.37 million[35] - Cash outflows from financing activities totaled $77.07 million, up from $48.89 million in the prior period, highlighting increased financial obligations[35] - Cash inflows from financing activities amounted to $4.75 million, a substantial increase from $765,300 in the previous period[35] - Cash paid for dividends, profits, or interest totaled $46.71 million, slightly down from $48 million year-over-year[35] - The impact of exchange rate changes on cash and cash equivalents was a negative $1.32 million, compared to a negative $975,710 in the previous period[35] - The beginning cash and cash equivalents balance was $1.13 billion, showing a slight decrease from $1.14 billion year-over-year[35]